Bibb J A, Snyder G L, Nishi A, Yan Z, Meijer L, Fienberg A A, Tsai L H, Kwon Y T, Girault J A, Czernik A J, Huganir R L, Hemmings H C, Nairn A C, Greengard P
Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10021, USA.
Nature. 1999 Dec 9;402(6762):669-71. doi: 10.1038/45251.
The physiological state of the cell is controlled by signal transduction mechanisms which regulate the balance between protein kinase and protein phosphatase activities. Here we report that a single protein can, depending on which particular amino-acid residue is phosphorylated, function either as a kinase or phosphatase inhibitor. DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34. We find that DARPP-32 is converted into an inhibitor of PKA when phosphorylated at threonine 75 by cyclin-dependent kinase 5 (Cdk5). Cdk5 phosphorylates DARPP-32 in vitro and in intact brain cells. Phospho-Thr 75 DARPP-32 inhibits PKA in vitro by a competitive mechanism. Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents. Thus DARPP-32 is a bifunctional signal transduction molecule which, by distinct mechanisms, controls a serine/threonine kinase and a serine/threonine phosphatase.
细胞的生理状态由信号转导机制控制,这些机制调节蛋白激酶和蛋白磷酸酶活性之间的平衡。在此我们报告,单一蛋白质可根据特定氨基酸残基的磷酸化情况,发挥蛋白激酶抑制剂或蛋白磷酸酶抑制剂的作用。多巴胺和环磷酸腺苷调节的磷蛋白(DARPP-32,相对分子质量32,000)在苏氨酸34被蛋白激酶A(PKA)磷酸化时,会转变为蛋白磷酸酶1的抑制剂。我们发现,当DARPP-32在苏氨酸75被细胞周期蛋白依赖性激酶5(Cdk5)磷酸化时,会转变为PKA的抑制剂。Cdk5可在体外和完整的脑细胞中使DARPP-32磷酸化。磷酸化苏氨酸75的DARPP-32在体外通过竞争机制抑制PKA。使用Cdk5特异性抑制剂或利用基因改造小鼠降低纹状体切片中磷酸化苏氨酸75的DARPP-32水平,会导致多巴胺诱导的PKA底物磷酸化增加以及峰值电压门控钙电流增强。因此,DARPP-32是一种双功能信号转导分子,通过不同机制控制一种丝氨酸/苏氨酸激酶和一种丝氨酸/苏氨酸磷酸酶。